Wire · opportunities
Federal Trade Commission – Caremark Agrees To Settle FTC Antitrust Case
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
The FTC secured an $8.5 billion settlement with Caremark, requiring the pharmacy benefit manager to overhaul rebate-driven practices that artificially inflated insulin prices. The settlement delinks PBM fees from list prices, mandates transparency, and allows plan sponsors to shift to cost-plus reimbursement models.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 20 Jul 2026 and 27 Jul 2026.
◆ ◆ The Wire takeaway
If you're building pharmacy, medication access or drug pricing transparency software, Caremark's forced shift to cost-plus reimbursement just killed the old playbook—and created a market for tools that handle non-rebate pricing, real-time cost visibility, and hub pharmacy coordination. Every other major PBM will face the same pressure within 18 months.
◆ Coverage
2 sources · first reported 20 Jul 2026 · latest 27 Jul 2026
◆ Related on Wire
◆ Topics